These results not only further support our conclusion, but also suggest the effect of mitophagy on glycolysis in lenvatinib-resistant HCC cells (CCHuh7R/CCPLC-PRF-5R) is targeted by ENO2, which has been verified in various cancers [33, 34]. Here, ENO2 is linked to hepatocellular carcinoma.